GPR119: a promising target for nonalcoholic fatty liver disease

No abstract is available for this paper.

• Publication year

  2016

• Venue

  The FASEB Journal

• Publication date

  2016-01-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1096/fj.15-273771PMID 26399788
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 Diabetes

  2014cited by this paper
• Flavonoid diosmetin increases ATP levels in kidney cells and relieves ATP depleting effect of ochratoxin A.

  2014cited by this paper
• GPR119 regulates genetic markers of fatty acid oxidation in cultured skeletal muscle myotubes.

  2013cited by this paper
• SREBP: a novel therapeutic target.

  2013cited by this paper
• GPR119 expression in normal human tissues and islet cell tumors: evidence for its islet-gastrointestinal distribution, expression in pancreatic beta and alpha cells, and involvement in islet function.

  2013cited by this paper
• Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?

  2013cited by this paper
• Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis

  2013cited by this paper
• GPR119 as a fat sensor.

  2012cited by this paper
• Redox implications of AMPK-mediated signal transduction beyond energetic clues

  2012cited by this paper
• AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice.

  2011influential reference
• Mechanism of AMPK Suppression of LXR-dependent Srebp-1c Transcription

  2011cited by this paper
• The AMPK signalling pathway coordinates cell growth, autophagy and metabolism

  2011cited by this paper
• Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications

  2010cited by this paper
• N-oleoyldopamine enhances glucose homeostasis through the activation of GPR119.

  2010cited by this paper
• GPR119 is required for physiological regulation of glucagon-like peptide-1 secretion but not for metabolic homeostasis.

  2009cited by this paper
• Structural insight into the autoinhibition mechanism of AMP-activated protein kinase

  2009influential reference
• AMPK: an emerging drug target for diabetes and the metabolic syndrome.

  2009cited by this paper
• GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice.

  2009cited by this paper
• AMP‐activated protein kinase suppresses LXR‐dependent sterol regulatory element‐binding protein‐1c transcription in rat hepatoma McA‐RH7777 cells

  2009cited by this paper
• Role of adenosine monophosphate‐activated protein kinase–p70 ribosomal S6 kinase‐1 pathway in repression of liver X receptor‐alpha–dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones

  2009influential reference
• Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis.

  2008cited by this paper
• A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release.

  2008cited by this paper
• GPR119, a novel G protein‐coupled receptor target for the treatment of type 2 diabetes and obesity

  2008cited by this paper
• Biological role of liver X receptors.

  2008cited by this paper
• SREBPs: the crossroads of physiological and pathological lipid homeostasis.

  2008cited by this paper
• A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release.

  2007cited by this paper
• Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents.

  2006cited by this paper
• Liver X receptors as integrators of metabolic and inflammatory signaling.

  2006cited by this paper
• Intracellular nucleotide and nucleotide sugar contents of cultured CHO cells determined by a fast, sensitive, and high-resolution ion-pair RP-HPLC.

  2006cited by this paper
• Polyphenols Stimulate AMP-Activated Protein Kinase, Lower Lipids, and Inhibit Accelerated Atherosclerosis in Diabetic LDL Receptor–Deficient Mice

  2006cited by this paper
• Protein sensors for membrane sterols.

  2006cited by this paper
• Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor.

  2005cited by this paper
• Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α

  2003cited by this paper
• SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.

  2002cited by this paper
• Insulin signalling and the regulation of glucose and lipid metabolism

  2001cited by this paper
• Role of AMP-activated protein kinase in mechanism of metformin action.

  2001cited by this paper
• Role of LXRs in control of lipogenesis.

  2000cited by this paper
• Mouse liver cell culture

  1981cited by this paper

• Human milk fat substitutes improve obesity-related NAFLD by enriching LPC 18:2 to activate hepatic GPR119-AMPK signaling.

  2026cites this paper
• DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy.

  2025cites this paper
• Discovery of MKP10241, a Novel Small Molecule Targeting the GPR119/Incretin Axis to Treat Metabolic Disorders.

  2025cites this paper
• Nonclassical Cannabinoid Receptors: Modern Concepts of Signal Transmission Functions and Mechanisms

  2025cites this paper
• Characterization of a new lyso-ornithine lipid from the shipworm symbiont Teredinibacter turnerae

  2025cites this paper
• Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

  2024cites this paper
• What is holding back preclinical GPR119 agonists from their potential as the therapeutics of type 2 diabetes?

  2024cites this paper
• Pathophysiological Relationship between Type 2 Diabetes Mellitus and Metabolic Dysfunction-Associated Steatotic Liver Disease: Novel Therapeutic Approaches

  2024cites this paper
• GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates

  2024cites this paper
• Probiotic interventions promote metabolic health in high fat-fed hamsters in association with gut microbiota and endocannabinoidome alterations.

  2023cites this paper
• SREBP inhibitors: an updated patent review for 2008-present

  2023cites this paper
• Regulation and targeting of SREBP-1 in hepatocellular carcinoma

  2023cites this paper
• GPR119 activation by DA-1241 alleviates hepatic and systemic inflammation in MASH mice through inhibition of NFκB signaling.

  2023cites this paper
• Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis.

  2023cites this paper
• DA-1241, a Novel GPR119 Agonist, Improves Hyperglycaemia by Inhibiting Hepatic Gluconeogenesis and Enhancing Insulin Secretion in Diabetic Mice

  2022cites this paper
• Imipramine Accelerates Nonalcoholic Fatty Liver Disease, Renal Impairment, Diabetic Retinopathy, Insulin Resistance, and Urinary Chromium Loss in Obese Mice

  2021cites this paper
• GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide

  2021cites this paper
• Phytocannabinoids—A Green Approach toward Non-Alcoholic Fatty Liver Disease Treatment

  2021cites this paper
• Doxepin Exacerbates Renal Damage, Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Urinary Chromium Loss in Obese Mice

  2021cites this paper
• Therapeutic Potential of G Protein‐Coupled Receptors Against Nonalcoholic Steatohepatitis

  2021cites this paper
• Clozapine Worsens Glucose Intolerance, Nonalcoholic Fatty Liver Disease, Kidney Damage, and Retinal Injury and Increases Renal Reactive Oxygen Species Production and Chromium Loss in Obese Mice

  2021cites this paper
• Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease

  2021cites this paper
• A novel GPR119 agonist DA-1241 preserves pancreatic function via the suppression of ER stress and increased PDX1 expression.

  2021cites this paper
• The Ameliorative Effects of Saikosaponin in Thioacetamide-Induced Liver Injury and Non-Alcoholic Fatty Liver Disease in Mice

  2021cites this paper
• Antidiabetic Therapy in the Treatment of NASH

  2020cites this paper
• GPCRs get Fatty: The Role of G Protein-Coupled Receptor Signaling in the Development and Progression of Nonalcoholic Fatty Liver Disease.

  2020cites this paper
• GSK1292263 | MedChemExpress

  2020cites this paper
• Modeling Diet-Induced Metabolic Syndrome in Rodents.

  2020cites this paper
• Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis

  2020cites this paper
• Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis

  2019cites this paper
• Targeting GPCRs Activated by Fatty Acid-Derived Lipids in Type 2 Diabetes.

  2019cites this paper
• The effects of oleoylethanolamide, an endogenous PPAR‐α agonist, on risk factors for NAFLD: A systematic review

  2019influential citation
• Antihyperlipidemic Activity of Ligularia fischeri Extract in Mice Fed a High-Carbohydrate Diet

  2019cites this paper
• Theracurmin (Highly Bioavailable Curcumin) Prevents High Fat Diet-Induced Hepatic Steatosis Development in Mice

  2019cites this paper
• The Expanded Endocannabinoid System/Endocannabinoidome as a Potential Target for Treating Diabetes Mellitus

  2019cites this paper
• Chapter 4 Co-administration of APD 668 , a G protein-coupled receptor 119 agonist and Linagliptin , a DPPIV inhibitor , prevents progression of steatohepatitis in mice fed on a high transfat diet

  2018cites this paper
• G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus

  2018influential citation
• Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.

  2018cites this paper
• Therapeutic application of GPR119 ligands in metabolic disorders

  2018cites this paper
• GPR119 agonist enhances gefitinib responsiveness through lactate-mediated inhibition of autophagy

  2018cites this paper
• G protein‐coupled receptor 119 is involved in RANKL‐induced osteoclast differentiation and fusion

  2018cites this paper
• Combination of APD668, a G protein-coupled receptor 119 agonist with linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in a murine model of non-alcoholic steatohepatitis with diabetes

  2018cites this paper
• Design, synthesis, and biological evaluation of 2‐(4‐(methylsulfonyl)phenyl)pyridine derivatives as GPR119 agonists

  2018cites this paper
• Modulation of the Oxidative Stress and Lipid Peroxidation by Endocannabinoids and Their Lipid Analogues

  2018cites this paper
• YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model

  2017influential citation
• Cannabinoid Receptor-Related Orphan G Protein-Coupled Receptors.

  2017cites this paper
• YH18421, a novel GPR119 agonist exerts sustained glucose lowering and weight loss in diabetic mouse model

  2017influential citation
• APD668, a G protein‐coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high‐trans fat diet induced steatohepatitis model in C57BL/6 mice

  2017cites this paper
• Fatty Acid Binding Protein-1 (FABP1) and the Human FABP1 T94A Variant: Roles in the Endocannabinoid System and Dyslipidemias

  2016cites this paper